Abstract:The metabolism of the 5-lipoxygenase inhibitor, 4-(3-(4-(2-methyl-1H-imidazol-1-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide (CJ-13,610), was investigated in liver microsomes from human and preclinical species in an effort to compare metabolite profiles and evaluate the in vitro-in vivo correlation for metabolic clearance. Overall, the metabolite profile of CJ-13,610 was comparable across the species tested with multiple oxidative metabolites observed, including sulfoxidation. The sulfoxidation kinetics characterized in rat, dog, and human liver microsomes (HLM) indicated a low apparent Michaelis-Menten constant (K(m, app)) of 4 to 5 microM. Results from cDNA-expressed cytochrome P450 (P450) studies indicated that the metabolism in HLM was primarily mediated by CYP3A4 and 3A5. A subsequent in vitro study using ketoconazole as an inhibitor of CJ-13,610 sulfoxidation corroborated the CYP3A4/5-mediated pathway (IC(50) = 7 nM). Assessment of multiple methods for predicting the human pharmacokinetic profile observed with CJ-13,610 after a 30-mg single oral dose indicated that clearance scaled from human liver microsomes yielded a better prediction when coupled with a Vd(ss) term that was scaled from dog [area under the concentration-time curve (AUC) and half-life within 1.3-fold of actual] versus a Vd(ss) term obtained from rat. Single-species allometric scaling of clearance and Vd(ss) from dog pharmacokinetic studies was equally predictive, whereas scaling from rat resulted in underpredictions of both AUC and maximal concentration (C(max)). Results from these studies support the strategy of predicting human pharmacokinetics using human liver microsomal intrinsic clearance data. More importantly, results from the present investigation enabled the selection of alternative drug candidates from the chemical series via in vitro screening, while subsequently eliminating costly routine preclinical in vivo studies.

Pharmacokinetic, distribution, metabolism, and excretion of (Z)-2-amino-1,5-dihydro-1-methyl-5-[4-(mesyl)benzylidene]-4H-imidazol-4-one mesilate (ZLJ-601) in Sprague-Dawley rats.

Pharmacokinetics and Metabolism of Jatrorrhizine, A Gastric Prokinetic Drug Candidate

[Pharmacological Activities of Z-ligustilide and Metabolites in Rats].

Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a validated LC-MS/MS method

Pharmacokinetics, Tissue Distribution and Excretion of ACT001 in Sprague-Dawley Rats and Metabolism of ACT001.

The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.

Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor.

The absolute bioavailability investigation of LS177 in rats using ultra-performance liquid chromatography-tandem mass spectrometry.

In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase

Identification of circulatory and excretory metabolites of a novel nitric oxide donor ZJM-289 in rat plasma, bile, urine and faeces by liquid chromatographytandem mass spectrometry

Spray-dried Oil-in-water Emulsion to Improve the Intestinal Absorption and Oral Bioavailability of ZLR-8, a Nitric Oxide-Releasing Derivative of Diclofenac

Anti-inflammatory Effect and Mechanism of Compound ZLJ-601

Identification of Metabolites of Zhali Nusi Prescription in Rat Plasma, Bile,urine and Feces after Oral Administration

Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib

Study on Pharmacokinetics of Liguzinediol and Four Metabolites in Rats by UFLC–MS/MS

Preclinical Pharmacokinetic Evaluation and Metabolites Identification of Methyl Salicylate-2-o-β-d-lactoside in Rats Using LC-MS/MS and Q-TOF-MS Methods.

Study of the in Vitro Metabolism of Tj0711 Using Ultra High Performance Liquid Chromatography with Quadrupole Time-Of-Flight and Ultra Fast Liquid Chromatography with Quadrupole Linear Ion Trap Mass Spectrometry

Pharmacokinetic, Bioavailability, and Metabolism Studies of Lusianthridin, a Dihydrophenanthrene Compound, in Rats by Liquid Chromatography/electrospray Ionization Tandem Mass Spectrometry

Assay Development for Determination of DZ2002, a New Reversible SAHH Inhibitor, and Its Acid Metabolite DZA in Blood and Application to Rat Pharmacokinetic Study

Pharmacokinetic Profile of Z-ligustilide in Rat Plasma and Brain Following Oral Administration

Identification of Liguzinediol Metabolites in Rats by Ultra Performance Liquid Chromatography/quadrupole-Time-of-flight Mass Spectrometry